FENNEC PHARMACEUTICALS INC. Active Patents
8 granted patents the USPTO still lists as patented, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2024-03-15: Application 18606860; Invention THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS; Applicant Fennec Pharmaceuticals, Inc.; Status Patented Case.
- 2022-11-22: Application 17992715; Invention ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF; Applicant Fennec Pharmaceuticals Inc.; Status Patented Case.
- 2022-11-22: Application 17992707; Invention THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS; Applicant Fennec Pharmaceuticals Inc.; Status Patented Case.
- 2022-11-22: Application 17992703; Invention THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS; Applicant Fennec Pharmaceuticals Inc.; Status Patented Case.
| Filed | Application | Invention | Applicant | Status | Granted | Patent | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-15 | 18606860 | THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS | Fennec Pharmaceuticals, Inc. | Patented Case | 2025-05-27 | 12311026 | US20240216511A1 | Alexander Smith Rostislav Christov Raykov | United States United States | LAZARO, DOMINIC |
| 2022-11-22 | 17992715 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals Inc. | Patented Case | 2024-04-23 | 11964018 | US20230158145A1 | Alexander Smith | United States | LAZARO, DOMINIC |
| 2022-11-22 | 17992707 | THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS | Fennec Pharmaceuticals Inc. | Patented Case | 2024-05-28 | 11992530 | US20230094886A1 | Alexander Smith | United States | LAZARO, DOMINIC |
| 2022-11-22 | 17992703 | THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS | Fennec Pharmaceuticals Inc. | Patented Case | 2024-06-04 | 11998604 | US20230094842A1 | Alexander Smith | United States | LAZARO, DOMINIC |
| 2022-07-22 | 17871825 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals Inc. | Patented Case | 2023-04-04 | 11617793 | US20220378915A1 | Thomas Claiborne Lovelace Joseph Alexander Moore III Christopher McKinnon Lee Daniel Logan Kirschner | United States United States United States United States | VANOY, TIMOTHY C |
| 2022-06-24 | 17849477 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals Inc. | Patented Case | 2022-11-29 | 11510984 | US20220323586A1 | Thomas Claiborne Lovelace Joseph Alexander Moore III Christopher McKinnon Lee Daniel Logan Kirschner | United States United States United States United States | VANOY, TIMOTHY C |
| 2020-08-28 | 17005997 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals, Inc. | Patented Case | 2022-04-05 | 11291728 | US20210015923A1 | Thomas Claiborne LOVELACE Joseph Alexander MOORE III Christopher McKinnon LEE Daniel Logan KIRSCHNER | United States United States United States United States | VANOY, TIMOTHY C |
| 2019-07-01 | 16458261 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | FENNEC PHARMACEUTICALS INC. | Patented Case | 2020-10-06 | 10792363 | US20200009255A1 | Thomas Claiborne LOVELACE Joseph Alexander MOORE III Christopher McKinnon LEE Daniel Logan KIRSCHNER | United States United States United States United States | VANOY, TIMOTHY C |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |